INVIVYD, INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- INVIVYD, INC. stock issued during period, value, new issues for the quarter ending 2024-03-31 was $39.06M.
- INVIVYD, INC. stock issued during period, value, new issues for the quarter ending 2021-06-30 was $66.00K.
- INVIVYD, INC. stock issued during period, value, new issues for fiscal 2024 was $39.06M, a 16173.75% increase from fiscal 2023.
- INVIVYD, INC. stock issued during period, value, new issues for fiscal 2023 was $240.00K.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2024-12-31 | $39.06M 10-K · filed 2026-03-05 | |
| 2024-03-31 | $39.06M 10-Q · filed 2025-11-06 | |
| 2023-12-31 | $240.00K 10-K · filed 2025-03-20 | |
| 2021-12-31 | $66.00K 8-K · filed 2024-02-09 | |
| 2021-06-30 | $66.00K 10-Q · filed 2022-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |